Details of the Drug Combination

General Information of Drug Combination (ID: DCBT4CD)

Drug Combination Name
Pregabalin Oxycodone
Indication
Disease Entry Status REF
Cancer Phase 1 [1]
Component Drugs Pregabalin   DMDVP3B Oxycodone   DMXLKHV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pregabalin
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Approved [2]
Epilepsy 8A60-8A68 Approved [3]
Pain MG30-MG3Z Approved [3]
Postherpetic neuralgia 1E91.5 Approved [3]
Vulvodynia N.A. Approved [3]
Chronic pain MG30 Investigative [3]
Neuralgia N.A. Investigative [3]
Pregabalin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) TTFK1JQ CA2D1_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Pregabalin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
L-type amino acid transporter 1 (SLC7A5) DT48T0N LAT1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Indication(s) of Oxycodone
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [4]
Pain MG30-MG3Z Approved [5]
Back pain ME84.Z Phase 3 [6]
Oxycodone Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [9]
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Agonist [10]
------------------------------------------------------------------------------------
Oxycodone Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [11]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00637975) Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5484).
3 Pregabalin FDA Label
4 Oxycodone FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
6 ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
7 Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
8 Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
10 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
11 Chronic oxycodone induces integrated stress response in rat brain. BMC Neurosci. 2015 Sep 16;16:58. doi: 10.1186/s12868-015-0197-8.